NASDAQ:JYNT Joint (JYNT) Stock Price, News & Analysis $10.93 -0.11 (-1.00%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$10.93 0.00 (0.00%) As of 08/1/2025 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Joint Stock (NASDAQ:JYNT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Joint alerts:Sign Up Key Stats Today's Range$10.80▼$11.0050-Day Range$10.00▼$12.5152-Week Range$9.58▼$13.47Volume96,419 shsAverage Volume40,716 shsMarket Capitalization$167.23 millionP/E RatioN/ADividend YieldN/APrice Target$15.50Consensus RatingBuy Company Overview The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona. Read More Joint Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreJYNT MarketRank™: Joint scored higher than 71% of companies evaluated by MarketBeat, and ranked 260th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingJoint has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageJoint has only been the subject of 1 research reports in the past 90 days.Read more about Joint's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth381.82% Earnings GrowthEarnings for Joint are expected to grow by 381.82% in the coming year, from $0.11 to $0.53 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Joint is -18.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Joint is -18.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJoint has a P/B Ratio of 9.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Joint's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.64% of the float of Joint has been sold short.Short Interest Ratio / Days to CoverJoint has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Joint has recently decreased by 4.73%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJoint does not currently pay a dividend.Dividend GrowthJoint does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.64% of the float of Joint has been sold short.Short Interest Ratio / Days to CoverJoint has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Joint has recently decreased by 4.73%, indicating that investor sentiment is improving. News and Social Media2.0 / 5News Sentiment0.60 News SentimentJoint has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Joint this week, compared to 2 articles on an average week. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Joint insiders have not sold or bought any company stock.Percentage Held by Insiders27.90% of the stock of Joint is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.88% of the stock of Joint is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Joint's insider trading history. Receive JYNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Joint and its competitors with MarketBeat's FREE daily newsletter. Email Address JYNT Stock News HeadlinesCritical Comparison: Joint (NASDAQ:JYNT) & Select Medical (NYSE:SEM)August 1 at 3:45 AM | americanbankingnews.comThe Joint Corp. Expects to Restate Full Year 2024 and First Quarter 2025 Financial Statements ...July 30 at 7:36 PM | gurufocus.comDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts warn a programmable dollar could erase your privacy and control your spending. A free guide reveals how to protect your savings before the system goes live. | American Alternative (Ad)The Joint Corp. Expects to Restate Full Year 2024 and First Quarter 2025 Financial Statements due to Overestimated Noncash Impairment ChargesJuly 30 at 6:48 PM | globenewswire.comAccelerating the Evolution of Automotive Embodied Intelligence, Geely Auto Group Teams Up with StepFun for a Joint Showcase at the 2025 World Artificial Intelligence ConferenceJuly 30 at 3:05 PM | globenewswire.comAres Management Establishes Joint Venture With Savion to Invest in U.S. Solar Power GenerationJuly 28, 2025 | businesswire.comThe Joint Corp. to Host Conference Call on Thursday, August 7th to Discuss Second Quarter 2025 ResultsJuly 24, 2025 | uk.finance.yahoo.comThe Joint Corp. to Host Conference Call on Thursday, August 7th to Discuss Second Quarter 2025 ResultsJuly 24, 2025 | globenewswire.comSee More Headlines JYNT Stock Analysis - Frequently Asked Questions How have JYNT shares performed this year? Joint's stock was trading at $10.63 on January 1st, 2025. Since then, JYNT stock has increased by 2.8% and is now trading at $10.93. How were Joint's earnings last quarter? The Joint Corp. (NASDAQ:JYNT) announced its earnings results on Thursday, May, 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.01. The firm had revenue of $13.08 million for the quarter, compared to analysts' expectations of $13.02 million. Joint had a negative net margin of 9.86% and a positive trailing twelve-month return on equity of 1.60%. Read the conference call transcript. Is Joint buying back stock? Joint's board approved a share buyback program on Thursday, June 5th 2025, which authorizes the company to repurchase $5,000,000 in outstanding shares, according to EventVestor. This means that the company could buy up to 2.7% of its stock through open market purchases. Stock buyback programs are often a sign that the company's leadership believes its stock is undervalued. When did Joint IPO? Joint (JYNT) raised $20 million in an initial public offering on Tuesday, November 11th 2014. The company issued 3,000,000 shares at $6.50 per share. Roth Capital Partners and Feltl and Company acted as the underwriters for the IPO and Sanders Morris Harris was co-manager. Who are Joint's major shareholders? Joint's top institutional shareholders include Sanders Morris Harris LLC (0.08%) and Nisa Investment Advisors LLC (0.01%). View institutional ownership trends. How do I buy shares of Joint? Shares of JYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Joint own? Based on aggregate information from My MarketBeat watchlists, some other companies that Joint investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings5/08/2025Today8/02/2025Next Earnings (Estimated)8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - HMO Sub-IndustryTrading Current SymbolNASDAQ:JYNT CIK1612630 Webwww.thejoint.com Phone(480) 245-5960Fax480-513-7989Employees320Year FoundedN/APrice Target and Rating Average Price Target for Joint$15.50 High Price Target$16.00 Low Price Target$15.00 Potential Upside/Downside+41.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.58) Trailing P/E RatioN/A Forward P/E Ratio99.36 P/E GrowthN/ANet Income-$8.53 million Net Margins-9.86% Pretax Margin-1.79% Return on Equity1.60% Return on Assets0.41% Debt Debt-to-Equity RatioN/A Current Ratio1.59 Quick Ratio1.59 Sales & Book Value Annual Sales$51.90 million Price / Sales3.22 Cash Flow$0.65 per share Price / Cash Flow16.89 Book Value$1.20 per share Price / Book9.11Miscellaneous Outstanding Shares15,300,000Free Float11,033,000Market Cap$167.23 million OptionableOptionable Beta1.53 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:JYNT) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding The Joint Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Joint With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.